-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
9 views
Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies.
